BioCentury | Apr 7, 2021
Product Development

How COVID-19 brought China vaccine play CanSino onto the global stage

...unit of Aventis S.A., which merged with Sanofi-Synthelabo...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | May 18, 2017
Product R&D

Making cells compute

...which came out of a 2008 partnership between Amyris Biotechnologies Inc. (now Amyris Inc. ), sanofi-aventis Group...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Sleep apnea In vitro , rat and pig studies identified a phenoxyaminoindane-based SLC9A3 inhibitor that could help treat sleep apnea. Screening of a small molecule library in a cell-based assay, followed by chemical synthesis and...
BioCentury | Apr 4, 2016
Product Development

Portola's mitigating factors

...post-discharge significantly reduced VTE risk vs. placebo in the Phase III EXCLAIM trial completed by sanofi-aventis Group...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a...
...$375 million in milestones (see BioCentury, Dec. 14, 2009). Alopexx Pharmaceuticals LLC , Concord, Mass. sanofi-aventis Group...
BioCentury | Nov 18, 2013
Company News

Pfizer, Sanofi pulmonary, autoimmune news

...conception of the claimed cDNA could not occur until the full sequence was determined. In Sanofi-Aventis...
BioCentury | Oct 7, 2013
Company News

Sanofi, National Alliance for Life Sciences and Healthcare (AVIESAN) deal

...development of technology platforms to finance the work of researchers. In 2010, Sanofi - then sanofi-aventis...
BioCentury | Jul 15, 2013
Company News

Sanofi pharmaceuticals news

...Sanofi said that its Sanofi-Aventis R&D France project, which employs more than 5,000 positions, could lead...
BioCentury | May 2, 2013
Targets & Mechanisms

FGFR allosteric inhibition

...online April 15, 2013; doi:10.1016/j.ccr.2013.02.018 Contact: Françoise Bono, Sanofi Research and Development, Toulouse, France e-mail: francoise.bono@sanofi-aventis.com...
Items per page:
1 - 10 of 3110
BioCentury | Apr 7, 2021
Product Development

How COVID-19 brought China vaccine play CanSino onto the global stage

...unit of Aventis S.A., which merged with Sanofi-Synthelabo...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | May 18, 2017
Product R&D

Making cells compute

...which came out of a 2008 partnership between Amyris Biotechnologies Inc. (now Amyris Inc. ), sanofi-aventis Group...
BioCentury | Oct 20, 2016
Distillery Therapeutics

Neurology

INDICATION: Sleep apnea In vitro , rat and pig studies identified a phenoxyaminoindane-based SLC9A3 inhibitor that could help treat sleep apnea. Screening of a small molecule library in a cell-based assay, followed by chemical synthesis and...
BioCentury | Apr 4, 2016
Product Development

Portola's mitigating factors

...post-discharge significantly reduced VTE risk vs. placebo in the Phase III EXCLAIM trial completed by sanofi-aventis Group...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a...
...$375 million in milestones (see BioCentury, Dec. 14, 2009). Alopexx Pharmaceuticals LLC , Concord, Mass. sanofi-aventis Group...
BioCentury | Nov 18, 2013
Company News

Pfizer, Sanofi pulmonary, autoimmune news

...conception of the claimed cDNA could not occur until the full sequence was determined. In Sanofi-Aventis...
BioCentury | Oct 7, 2013
Company News

Sanofi, National Alliance for Life Sciences and Healthcare (AVIESAN) deal

...development of technology platforms to finance the work of researchers. In 2010, Sanofi - then sanofi-aventis...
BioCentury | Jul 15, 2013
Company News

Sanofi pharmaceuticals news

...Sanofi said that its Sanofi-Aventis R&D France project, which employs more than 5,000 positions, could lead...
BioCentury | May 2, 2013
Targets & Mechanisms

FGFR allosteric inhibition

...online April 15, 2013; doi:10.1016/j.ccr.2013.02.018 Contact: Françoise Bono, Sanofi Research and Development, Toulouse, France e-mail: francoise.bono@sanofi-aventis.com...
Items per page:
1 - 10 of 3110